Back to Search
Start Over
Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy.
- Source :
-
Eye (London, England) [Eye (Lond)] 2022 Oct; Vol. 36 (10), pp. 1945-1950. Date of Electronic Publication: 2021 Sep 28. - Publication Year :
- 2022
-
Abstract
- Purpose: The aim of this study was to assess the short-term effect of anti-vascular endothelial growth factor (VEGF) treatment on type 1 macular neovascularization (MNV) secondary to central serous chorioretinopathy (CSCR) and to identify potential predictive factors for treatment response using multimodal imaging.<br />Methods: Retrospective, multicentre study in CSCR patients with MNV detected by OCT-angiography and treated with anti-VEGF injections. Clinical and multimodal imaging data before and after anti-VEGF injections was reviewed. Univariate and multivariate linear regression analyses were performed to evaluate associations between the change in central macular thickness (CMT) after anti-VEGF therapy and other factors.<br />Results: Forty patients were included. One month after receiving a mean number of 2.7 anti-VEGF intravitreal injections, visual acuity increased significantly from 0.46 ± 0.3 logMAR at baseline to 0.38 ± 0.4 logMAR (p = 0.04). The CMT and foveal serous retinal detachment (SRD) decreased significantly from 330 ± 81.9 µm at baseline to 261.7 ± 63.1 µm after treatment (p < 0.001) and from 145.1 ± 98.8 µm at baseline to 52.6 ± 71.3 µm (p < 0.001), respectively. Subretinal fluid and/or intraretinal fluid were still present in 18 eyes (45%) one month after treatment. In the multivariate analysis, a higher SRD height was associated with a greater CMT change (p = 0.002) and a lower CMT change with the presence of subretinal hyperreflective material (SHRM) (p = 0.04).<br />Conclusion: Fluid resorption was incomplete in about half of the patients with MNV secondary to CSCR after anti-VEGF injections. Shallower SRD or the presence of SHRM were predictors of poor response to anti-VEGF.<br /> (© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Endothelial Growth Factors therapeutic use
Fluorescein Angiography
Humans
Intravitreal Injections
Neovascularization, Pathologic drug therapy
Retrospective Studies
Tomography, Optical Coherence
Central Serous Chorioretinopathy complications
Central Serous Chorioretinopathy drug therapy
Retinal Detachment drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5454
- Volume :
- 36
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Eye (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 34584236
- Full Text :
- https://doi.org/10.1038/s41433-021-01778-6